Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Phanes Therapeutics Receives FDA Fast Track Designation for Spevatamig in Advanced ...

17 August 2026 · By · Wire by Fusion42

Published

17 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 17 August 2026 · Fusion42 review

Phanes Therapeutics has received FDA Fast Track designation for spevatamig in treating advanced and metastatic biliary tract carcinoma (BTC), highlighting the unmet need for novel BTC therapies. The designation adds to previous Fast Track and orphan drug recognitions for spevatamig in pancreatic cancers and supports ongoing Phase 2 trials including a collaboration with Merck.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You operate in immuno-oncology for gastrointestinal cancers. This FDA Fast Track designation opens expedited pathways for spevatamig, creating urgency to align trials and partnerships for quicker market entry.

◆ Coverage

1 source · 17 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfast-trackimmuno-oncologybiliary-tract-cancerphases-2-trialsFDA